156 related articles for article (PubMed ID: 29151933)
21. Dynamics of expression of ARID1A and ARID1B subunits in mouse embryos and in cells during the cell cycle.
Flores-Alcantar A; Gonzalez-Sandoval A; Escalante-Alcalde D; Lomelí H
Cell Tissue Res; 2011 Jul; 345(1):137-48. PubMed ID: 21647563
[TBL] [Abstract][Full Text] [Related]
22. ARID1A immunohistochemistry improves outcome prediction in invasive urothelial carcinoma of urinary bladder.
Faraj SF; Chaux A; Gonzalez-Roibon N; Munari E; Ellis C; Driscoll T; Schoenberg MP; Bivalacqua TJ; Shih IeM; Netto GJ
Hum Pathol; 2014 Nov; 45(11):2233-9. PubMed ID: 25175170
[TBL] [Abstract][Full Text] [Related]
23. Stathmin 1 expression predicts prognosis and benefits from adjuvant chemotherapy in patients with gallbladder carcinoma.
Bo X; Wang J; Fu Q; Wang Y; Liu H; Xu J
Oncotarget; 2017 Dec; 8(65):108548-108555. PubMed ID: 29312550
[TBL] [Abstract][Full Text] [Related]
24. B4GALT1 expression predicts prognosis and adjuvant chemotherapy benefits in muscle-invasive bladder cancer patients.
Xie H; Zhu Y; Zhang J; Liu Z; Fu H; Cao Y; Li G; Shen Y; Dai B; Xu J; Ye D
BMC Cancer; 2018 May; 18(1):590. PubMed ID: 29793447
[TBL] [Abstract][Full Text] [Related]
25. Loss of ARID1B and SMARCB1 expression are specific for the diagnosis of dedifferentiated/undifferentiated carcinoma in tumours of the upper gynaecological tract and cervix.
Kang EY; Tessier-Cloutier B; Duggan MA; Stewart CJR; Lee CH; Köbel M
Histopathology; 2021 Aug; 79(2):160-167. PubMed ID: 33432679
[TBL] [Abstract][Full Text] [Related]
26. CCND1/CyclinD1 status in metastasizing bladder cancer: a prognosticator and predictor of chemotherapeutic response.
Seiler R; Thalmann GN; Rotzer D; Perren A; Fleischmann A
Mod Pathol; 2014 Jan; 27(1):87-95. PubMed ID: 23887292
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer.
Li Y; Yao Q; Zhang L; Mo S; Cai S; Huang D; Peng J
Oncologist; 2020 Dec; 25(12):e1968-e1979. PubMed ID: 32926498
[TBL] [Abstract][Full Text] [Related]
28. Sp1 is overexpressed and associated with progression and poor prognosis in bladder urothelial carcinoma patients.
Zhu J; Lu Z; Ke M; Cai X
Int Urol Nephrol; 2022 Jul; 54(7):1505-1512. PubMed ID: 35467245
[TBL] [Abstract][Full Text] [Related]
29. Correlation between ARID1B gene mutation (p.A460, p.V215G) and prognosis of high-risk refractory neuroblastoma.
Zhang Y; Chen M; Huang D; Gu H; Yi Y; Meng X
Cell Biol Int; 2023 Jul; 47(7):1222-1228. PubMed ID: 36883912
[TBL] [Abstract][Full Text] [Related]
30. Immune Cell-Associated Protein Expression Helps to Predict Survival in Muscle-Invasive Urothelial Bladder Cancer Patients after Radical Cystectomy and Optional Adjuvant Chemotherapy.
Taubert H; Eckstein M; Epple E; Jung R; Weigelt K; Lieb V; Sikic D; Stöhr R; Geppert C; Weyerer V; Bertz S; Kehlen A; Hartmann A; Wullich B; Wach S
Cells; 2021 Jan; 10(1):. PubMed ID: 33467469
[TBL] [Abstract][Full Text] [Related]
31. Galectin-9 as a prognostic and predictive biomarker in bladder urothelial carcinoma.
Liu Y; Liu Z; Fu Q; Wang Z; Fu H; Liu W; Wang Y; Xu J
Urol Oncol; 2017 Jun; 35(6):349-355. PubMed ID: 28347658
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of
Ecke TH; Kiani A; Schlomm T; Friedersdorff F; Rabien A; Jung K; Kilic E; Boström P; Tervahartiala M; Taimen P; Gleichenhagen J; Johnen G; Brüning T; Koch S; Roggisch J; Wirtz RM
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33050010
[TBL] [Abstract][Full Text] [Related]
33. Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer.
Sun D; Tian L; Zhu Y; Wo Y; Liu Q; Liu S; Li H; Hou H
Mol Med; 2020 Aug; 26(1):78. PubMed ID: 32791957
[TBL] [Abstract][Full Text] [Related]
34. Impact of adjuvant chemotherapy on patients with pathological Stage T3b and/or lymph node metastatic bladder cancer after radical cystectomy.
Tabata M; Ikeda M; Urakami S; Takahashi S; Sakaguchi K; Kurosawa K; Okaneya T
Jpn J Clin Oncol; 2015 Oct; 45(10):963-7. PubMed ID: 26130451
[TBL] [Abstract][Full Text] [Related]
35. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.
Sung JY; Sun JM; Chang Jeong B; Il Seo S; Soo Jeon S; Moo Lee H; Yong Choi H; Young Kang S; Choi YL; Young Kwon G
Urol Oncol; 2014 Jan; 32(1):49.e23-31. PubMed ID: 24360661
[TBL] [Abstract][Full Text] [Related]
36. Two related ARID family proteins are alternative subunits of human SWI/SNF complexes.
Wang X; Nagl NG; Wilsker D; Van Scoy M; Pacchione S; Yaciuk P; Dallas PB; Moran E
Biochem J; 2004 Oct; 383(Pt 2):319-25. PubMed ID: 15170388
[TBL] [Abstract][Full Text] [Related]
37. Role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma and the prognostic significance of C-reactive protein: A multi-institutional, retrospective study.
Fujita K; Inamoto T; Yamamoto Y; Tanigawa G; Nakayama M; Mori N; Tsujihata M; Azuma H; Nonomura N; Uemura M
Int J Urol; 2015 Nov; 22(11):1006-12. PubMed ID: 26153093
[TBL] [Abstract][Full Text] [Related]
38. Selecting the Best Candidates for Cisplatin-based Adjuvant Chemotherapy After Radical Cystectomy Among Patients with pN+ Bladder Cancer.
Afferi L; Lonati C; Montorsi F; Briganti A; Necchi A; Mari A; Minervini A; Tellini R; Campi R; Schulz GB; Black PC; di Trapani E; de Cobelli O; Karnes RJ; Ahmed M; Mir MC; Algarra MA; Rink M; Zamboni S; Mondini F; Simeone C; Antonelli A; Tafuri A; Krajewski W; Małkiewicz B; Xylinas E; Soria F; Sanchez Salas R; Arora A; Cathelineau X; Hendricksen K; Ammiwala M; Borghesi M; Chierigo F; Teoh JY; Mattei A; Albisinni S; Roghmann F; Roumiguié M; Bajeot AS; Maier E; Aziz A; Hurle R; Contieri R; Pradere B; Carando R; Poyet C; Alvarez-Maestro M; D'Andrea D; Shariat SF; Moschini M;
Eur Urol Oncol; 2022 Dec; 5(6):722-725. PubMed ID: 35715319
[TBL] [Abstract][Full Text] [Related]
39. Investigation of eligibility for adjuvant therapy from real-world data of patients with urothelial carcinoma undergoing radical cystectomy and radical nephroureterectomy.
Matsue T; Kato M; Kosugi Y; Ishizaki K; Masuda H; Yamamoto S; Takeyama Y; Yukimatsu N; Otoshi T; Yamasaki T; Kuratsukuri K; Uchida J
Jpn J Clin Oncol; 2024 Feb; 54(2):182-191. PubMed ID: 37967156
[TBL] [Abstract][Full Text] [Related]
40. ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy.
Klatte T; Seitz C; Rink M; Rouprêt M; Xylinas E; Karakiewicz P; Susani M; Shariat SF
J Urol; 2015 Nov; 194(5):1456-62. PubMed ID: 26162296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
